Clinical trials: Degenerative Conditions, Neurologic
Parkinson's Disease (PD)
Phase I Clinical Study of NouvNeu001 Injection for the Treatment of Moderate-to-Advanced Parkinson's Disease in Patients Who Have Previously Undergone Deep Brain Stimulation or Deep Brain Nucleus Lesioning Surgery
This clinical trial is designed to evaluate the safety, tolerability and preliminary efficacy of a single injection of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in patients with Parkinson's Disease who have…
- Trial name
- NCT07550374
- Testing
- NouvNeu001 injection
- Where
- China
- Volunteers
- 10 people
- Sponsor
- iRegene Therapeutics Co., Ltd.
Alzheimer Disease
A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-63733657 in Healthy Subjects and Subjects With Alzheimer's Disease
The purpose of this study is to assess the safety and tolerability of JNJ-63733657 following single ascending intravenous (IV) dose administration in healthy subjects (Part 1) and multiple ascending IV dose administrations in…
- Trial name
- NCT03375697
- Testing
- JNJ-63733657
- Where
- 7 sites in Belgium, Germany and 2 more
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Leber Congenital Amaurosis 10, Blindness
An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) With LCA10 Caused by Mutations in the CEP290 Gene.
PQ-110-005 (BRIGHTEN) is an open-label, dose escalation and double-masked, randomized, controlled study evaluating safety and tolerability of sepofarsen administered via intravitreal (IVT) injection in pediatric subjects (<8…
- Conditions
- Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis, Vision Disorders
- Trial name
- BRIGHTEN (NCT04855045)
- Testing
- sepofarsen
- Where
- 9 sites in Belgium, Brazil and 5 more
- Volunteers
- 15 people
- Sponsor
- ProQR Therapeutics
Progressive Supranuclear Palsy
Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011
The study will be conducted by the Sponsor to evaluate Twelve-months Long-Term Safety and Efficacy of GV1001 (1.12 mg) administered subcutaneously as a treatment for Progressive Supranuclear Palsy(PSP).
- Trial name
- NCT06235775
- Testing
- GV1001 1.12mg
- Where
- 5 sites in South Korea
- Volunteers
- 67 people
- Sponsor
- GemVax & Kael
Parkinson's Disease
Azilect® (Rasagiline) in Levodopa-treated Parkinson's Patients With Motor Fluctuations in China
The rationale for conducting this study is to evaluate the efficacy, tolerability, and safety of rasagiline compared to placebo in levodopa-treated Parkinson's Disease (PD) Chinese patients with motor fluctuations.
- Trial name
- CHORAL (NCT01479530)
- Testing
- Azilect®
- Where
- 18 sites in China
- Volunteers
- 321 people
- Sponsor
- H. Lundbeck A/S
Alzheimer's Disease
Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease.
This study will evaluate compliance, tolerability, safety, efficacy and caregiver burden of rivastigmine patch 10 cm² treatment in people with Alzheimer's disease (MMSE 10-26) initiating therapy for the first time with a…
- Trial name
- CARE (NCT00731224)
- Testing
- Rivastigmine transdermal patch
- Where
- 40 sites in Australia, Malaysia and 3 more
- Volunteers
- 380 people
- Sponsor
- Novartis Pharmaceuticals
Generalized Myasthenia Gravis
A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
The purpose of this study is to evaluate the efficacy and safety of B007 in subjects with generalized myasthenia gravis.
- Trial name
- NCT06447597
- Testing
- B007
- Where
- 18 sites in China
- Volunteers
- 104 people
- Sponsor
- Shanghai Jiaolian Drug Research and Development Co., Ltd
Alzheimer's Disease
Study Of Rosiglitazone XR In Subjects With Mild-to-Moderate Alzheimers
This is a Phase III, multicenter, open-label extension, single-group study in male and female outpatients with mild-to-moderate Alzheimer's disease (AD) who have completed AVA105640.
- Trial name
- NCT00550420
- Testing
- Rosiglitazone XR
- Where
- 70 sites in United States, Austria and 16 more
- Volunteers
- 331 people
- Sponsor
- GlaxoSmithKline
Retinal Degeneration, Retinitis Pigmentosa
Safety & Efficacy of Subretinal Implants for Partial Restoration of Vision in Blind Patients
Patients who are legally blind, caused by retinal degeneration of photoreceptor rods \& cones (e.g. Retinitis pigmentosa), receive a subretinal implant to restore vision partially.
- Trial name
- NCT01497379
- Testing
- surgical implantation of subretinal device
- Where
- Hong Kong
- Volunteers
- 2 people
- Sponsor
- Retina Implant AG
Spinal Cord Stimulation, Deep Brain Stimulation
Implantable Systems Performance Registry
The Implantable Systems Performance Registry (ISPR) was developed to evaluate the long-term reliability and performance of market-released Medtronic Neuromodulation infusion and stimulation products.
- Conditions
- Spinal Cord Stimulation, Deep Brain Stimulation, Drug Infusion (Implantable Pumps), Sacral Neuromodulation
- Trial name
- ISPR (NCT00959296)
- Testing
- Various
- Where
- 50 sites in United States, Austria and 5 more
- Volunteers
- 10,981 people
- Sponsor
- MedtronicNeuro
Parkinson's Disease, Quality of Life
Study of the Application of Magnetic Fields for the Treatment of Parkinson's Disease
The purpose of this study is to see if a device called the Resonator can help to improve aspects of health and quality of life that are relevant to patients with Parkinson's disease.
- Trial name
- NCT00863226
- Testing
- Resonator Device
- Where
- 6 sites in United States
- Volunteers
- 72 people
- Sponsor
- pico-tesla Magnetic Therapies, LLC
Parkinson's Disease
The Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations
Patients will be randomised to receive either placebo or the study drug for a period of 30 weeks, in addition to their standard Parkinsonian medications.
- Trial name
- NCT00286897
- Testing
- E2007
- Where
- 118 sites in Austria, Belgium and 15 more
- Volunteers
- 702 people
- Sponsor
- Eisai Limited
Neovascular Age-related Macular Degeneration
Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)
The study evaluated the efficacy and safety of two different dosing regimens of ranibizumab (either monthly injections or injections as-needed based on the stability of a patient's vision) in Chinese patients with wet age-related…
- Trial name
- DRAGON (NCT01775124)
- Testing
- Ranibizumab
- Where
- 23 sites in China
- Volunteers
- 332 people
- Sponsor
- Novartis Pharmaceuticals
AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis (MG)
ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
This study is part of the ADAPT Forward platform study (NCT07294170). ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis.
- Conditions
- AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis (MG), MG - Myasthenia Gravis, gMG
- Trial name
- ADAPT Forward2 (NCT07673627)
- Testing
- Empasiprubart IV, Efgartigimod PH20 SC PFS
- Where
- 14 sites in United States, Belgium and 4 more
- Volunteers
- 40 people
- Sponsor
- argenx
Alzheimer Disease, Dementia
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
The main purpose of this study is to determine if participants who previously took donanemab get clinical benefit when they receive annual doses. For each participant, the study will last up to 2.5 years and will include 6 visits.
- Conditions
- Alzheimer Disease, Dementia, Plaque, Amyloid
- Trial name
- NCT07602582
- Testing
- Donanemab
- Where
- 62 sites in United States, Japan and 1 more
- Volunteers
- 550 people
- Sponsor
- Eli Lilly and Company
Chronic Disease, HIV/AIDS
Observational Pharmaco-Epidemiology Research & Analysis
Greater advances are needed in two separate but related areas in healthcare: 1) the Clinical Decision Support Systems that complement the EHR use in support of routine patient care, population management and disease management…
- Conditions
- Chronic Disease, HIV/AIDS, Liver Diseases, Inflammatory Bowel Diseases
- Trial name
- OPERA (NCT03813862)
- Testing
- Non-interventional (observational only)
- Where
- United States
- Volunteers
- 2,000,000 people, healthy volunteers welcome
- Sponsor
- Epividian
Alzheimer's Disease (AD)
A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-355
The purpose of this study is to evaluate the pharmacokinetics, safety and tolerability of CKD-355.
- Trial name
- NCT03802162
- Testing
- CKD-355A (D797/Memantine HCl 20mg), CKD-355B (D797/Memantine HCl 20mg), D797
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Alzheimer's Disease
Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Rilapladib (SB659032) in Healthy Volunteers
Rilapladib is a potent and selective inhibitor of lipoprotein associated phospholipase A2 (Lp-PLA2), which was previously under development for the treatment of atherosclerosis and is currently being developed for the treatment…
- Trial name
- NCT02130661
- Testing
- Rilapladib 25 mg, Rilapladib 250 mg, Itraconazole
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Essential Tremor, Parkinson's Disease
Global Registry: ExAblate Neuro MR Guided Focused Ultrasound (MRgFUS) of Neurological Disorders:
A global post approval study to collect safety and effectiveness data related to ExAblate Neuro for the treatment of certain disorders such as Essential Tremor, Parkinson's Movement Disorders, or Neuropathic Pain within the…
- Conditions
- Essential Tremor, Parkinson's Disease, Movement Disorders, Neuropathic Pain
- Trial name
- NCT03100474
- Where
- 9 sites in United States, Canada and 2 more
- Volunteers
- 500 people
- Sponsor
- InSightec
Refractory Generalized Myasthenia Gravis
Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis
To evaluate the safety and efficacy of eculizumab in the treatment of refractory generalized myasthenia gravis (gMG) as an extension study for the participants who previously completed Study ECU-MG-301(NCT01997229).
- Trial name
- NCT02301624
- Testing
- Eculizumab
- Where
- 60 sites in United States, Argentina and 15 more
- Volunteers
- 117 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.